all report title image
  • Published On : Jul 2022
  • Code : CMI5123
  • Industry : Pharmaceutical
  • Pages : 237
  • Formats :

Gastroparesis affects the spontaneous movement of muscles (motility) in the stomach. Gastroparesis can interfere with normal digestion and cause nausea, vomiting, and abdominal pain. It causes problems with blood sugar levels and nutrition. Dietary changes and medical treatment can help control the condition. Medications such as domperidone, erythromycin, anti-emetics, and others are used to treat gastroparesis condition.

The global gastroparesis treatment market is estimated to be valued at US$ 8,061.9 million in 2022 and expected to exhibit a CAGR of 3.6% during the forecast period (2022-2030).

Figure 1. Global Gastroparesis Treatment Market in Terms of Value (US$ million), By Region, 2022

Gastroparesis Treatment  | Coherent Market Insights

An increase in the number of pipeline products is estimated to drive the global gastroparesis treatment market growth during the forecast period.

  • The drug candidates which are developed and investigated for the treatment of gastroparesis have shown promising results in clinical trials. As a result, regulatory authorities such as the U.S. Food and Drug Administration (FDA) are awarding designations to the drug candidates. This is contribute to increase in number of pipeline products and thereby drive the growth of market. For instance, in February 2020, CinDome Pharma, Inc., a biopharmaceutical company, initiated a phase 2 clinical trial study to investigate the effect of oral CIN-102 (Deuterated domperidone (deudomperidone)) on gastric emptying and antral contractility in adults with diabetic gastroparesis.
CMI table icon

Gastroparesis Treatment Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 8,061.9 Mn
Historical Data for: 2017 to 2021 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 3.6% 2030 Value Projection: US$ 10,726.0 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug: Metoclopramide, Erythromycin, Domperidone, Others
  • By Type: Diabetic gastroparesis, Idiopathic gastroparesis, Post-surgical gastroparesis
  • By Route of Administration: Intravenous, Nasal, Oral
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Processa Pharmaceuticals, Inc., EVOKE PHARMA , Neurogastrx, Inc., Vanda Pharmaceuticals Inc., ANI Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc., Otsuka Holdings Co., Ltd., CinDome Pharma, Inc., PTC Therapeutics, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Atlantic Healthcare, and Salix Pharmaceuticals

Growth Drivers:
  • An increase in the number of pipeline products
  • The development of novel treatment
Restraints & Challenges:
  • Side effects associated with gastroparesis drugs

Figure 2. Global Gastroparesis Treatment Market Share (%), By Drug, 2022

Gastroparesis Treatment  | Coherent Market Insights

The development of novel treatment is anticipated to propel the global gastroparesis treatment market growth over the forecast period.

An increase in the prevalence of gastroparesis leads to an increase in the demand for novel treatment products. For instance, , in January 2018, according to National Institute of Diabetes and Digestive and Kidney Diseases, out of 100,000 people, about 10 men and about 40 women have gastroparesis in United States. Thus, developing newer products will create a lucrative opportunity for market players and drive the market growth. For instance, in November 2016, researchers at Emory University School of Medicine demonstrated the positive short-term outcomes for gastric per oral endoscopic pyloromyotomy or G-POEM, a minimally invasive procedure. The novel treatment showed significant improvement in symptoms of patients with gastroparesis (diabetic gastroparesis and idiopathic gastroparesis). Novel approaches/agents under evaluation for gastroparesis, include the prokinetic ghrelin agonist relamorelin, the prokinetic serotonergic agents velusetrag and prucalopride, the anti-emetic aprepitant, and per-endoscopic pyloric myotomy procedures.

Global Gastroparesis Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

  • Coronavirus disease (COVID-19) is a disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which commonly has symptoms such as fever, cough, and dyspnea
  • According to the 2020 annual report of EVOKE PHARMA, a biotechnology company, due to the restrictions imposed as a result of the COVID-19 pandemic, such as lockdown, its sales force has been restricted from conducting in-person interactions with certain physicians and customers. It has been restricted to conduct educational and promotional activities for Gimoti, indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. The continued spread of the COVID-19 and the measures taken by the governments of countries affected disrupted the raw material supply chain and the manufacturing or shipment of Gimoti for commercial sale which could have an adverse effect on the business, financial condition, and results of operations.

Global Gastroparesis Treatment Market: Restraint

Side effects associated with gastroparesis drugs are likely to hamper the market growth. Gastroparesis medications will vary in their side effects depending on the medication, dose, and patient’s other medical conditions. Fatigue, drowsiness, sedation, anxiety, and restlessness are some of the most prevalent side effects linked with prokinetics.

Key Players

Major players operating in the global gastroparesis treatment market include Processa Pharmaceuticals, Inc., EVOKE PHARMA, Neurogastrx, Inc., Vanda Pharmaceuticals Inc., ANI Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc., Otsuka Holdings Co., Ltd., CinDome Pharma, Inc., PTC Therapeutics, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Atlantic Healthcare, and Salix Pharmaceuticals.

Gastroparesis is a condition that affects the stomach muscles. It is a disease condition in which the stomach cannot empty itself of food in a normal manner. Nausea, vomiting, heartburn are the symptoms related to gastroparesis. It is most common in patients who have had diabetes for a long time and may also occur in other situations. Gastroparesis is caused due to viral infections, gastric (abdominal) surgery with injury to the vagus nerve, medications such as narcotics and some antidepressants, etc.

Market Dynamics

Strong promising pipelines developed by key players for gastroparesis treatment are anticipated to drive the gastroparesis treatment market growth. For instance, in October 2021, Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced that the company received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 2a clinical trial of PCS12852 in patients with moderate to severe gastroparesis. A clinical trial study conducted by Processa Pharmaceuticals, Inc. for PCS12852 is in phase 2. PCS12852 is a 5-hydroxytryptamine 4 (5-HT4) receptor agonist. PCS12852 is indicated for the treatment of gastroparesis. Moreover, a surge in the number of patents for gastroparesis is likely to augment the market growth. For instance, in April 2018, EVOKE PHARMA, a specialty pharmaceutical company focused on the treatment of gastrointestinal (GI) d­­iseases, announced that the European Patent Office issued a decision to Grant European Union (EU) patent no. 2747561 for Gimoti, covering formulations of metoclopramide for the intranasal delivery for the treatment of symptoms associated with diabetic gastroparesis, specifically for women. In addition, strategies adopted by key players such as acquisition, partnership, etc. are likely to drive the market growth. For instance, in October 2016, Allergan a pharmaceutical company acquired Motus Therapeutics, a gastrointestinal disease subsidiary of Rhythm Holding Company, following positive phase 2b trial results of Motus’ investigational treatment of diabetic gastroparesis.

Key features of the study:

  • This report provides an in-depth analysis of the global gastroparesis treatment market, market size (US$ Mn), and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global gastroparesis treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, strategies.
  • Key companies covered as a part of this study include Processa Pharmaceuticals, Inc., EVOKE PHARMA, Neurogastrx, Inc., Vanda Pharmaceuticals Inc., ANI Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc., Otsuka Holdings Co., Ltd., CinDome Pharma, Inc., PTC Therapeutics, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Atlantic Healthcare, and Salix Pharmaceuticals
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global gastroparesis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global gastroparesis treatment

Detailed Segmentation:

  • Global Gastroparesis Treatment Market, By Drug:
    • Metoclopramide
    • Erythromycin
    • Domperidone
    • Others
  • Global Gastroparesis Treatment Market, By Type:
    • Diabetic gastroparesis
    • Idiopathic gastroparesis
    • Post-surgical gastroparesis
  • Global Gastroparesis Treatment Market, By Route of Administration:
    • Intravenous
    • Nasal
    • Oral
  • Global Gastroparesis Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Gastroparesis Treatment Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Processa Pharmaceuticals, Inc.*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • EVOKE PHARMA
    • Neurogastrx, Inc.
    • Vanda Pharmaceuticals Inc.
    • ANI Pharmaceuticals, Inc.
    • Takeda Pharmaceutical Company Limited
    • GlaxoSmithKline plc.
    • Otsuka Holdings Co., Ltd.
    • CinDome Pharma, Inc.
    • PTC Therapeutics
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Atlantic Healthcare
    • Salix Pharmaceuticals

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global gastroparesis treatment market is estimated to be valued at US$ 8,061.9 million in 2022 and expected to exhibit a CAGR of 3.6% between 2022 and 2030.
Factors such as strong pipeline products are projected to boost the market growth over the forecast period.
The metoclopramide segment is expected to hold a major market share in the market in 2022.
The major factors hampering the growth of the market include side effects related to gastroparesis drugs.
Major players operating in the market include Processa Pharmaceuticals, Inc., EVOKE PHARMA, Neurogastrx, Inc., Vanda Pharmaceuticals Inc., ANI Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc., Otsuka Holdings Co., Ltd., CinDome Pharma, Inc., PTC Therapeutics, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Atlantic Healthcare, and Salix Pharmaceuticals.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo